Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
Tim Hempel, Lluı́s Raich, Simon Olsson, Nurit P. Azouz, Andrea M. Klingler, Markus Hoffmann, Stefan Pöhlmann, Marc E. Rothenberg, Frank Noé
Abstract
experiments and consistent with previous virus cell entry assays. Our TMPRSS2-drug structures are made public to guide the design of more potent and specific inhibitors.
Topics & Concepts
TMPRSS2BiopharmaceuticalChemistryPharmacologyIn vitroBiochemistryBiologyCoronavirus disease 2019 (COVID-19)MedicineGeneticsInternal medicineDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery MethodsPharmacological Receptor Mechanisms and Effects